Business Monitor International


Sri Lanka Pharmaceuticals & Healthcare Report

Published 21 October 2014

  • 80 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
 
$1,295.00
Sri Lanka Pharmaceuticals & Healthcare Report

BMI View:   Sri Lanka's pharmaceutical sector has received investment from domestic and foreign - notably Indian - investors in recent years, as economic growth has picked up and the government focuse d on improving the domestic pharmaceutical secto r . W e therefore expect th at pharmaceutical and healthcare sector growth will outpace economic growth over the five-year forecast period. Improved relations with India, after the country abstained from voting on the UNHCR resolution, are likely to spur further investments from Indian hospital groups such as Fortis.

Headline Expenditure Projections

  • Pharmaceuticals: LKR67.70bn (USD524mn) in 2013, to LKR75.09bn (USD570mn) in 2014; +10.9% in local currency terms and 8.9% in US dollar terms over the five-year forecast period.

  • Healthcare: LKR261.04bn (USD2.02bn) in 2013, to LKR283.97bn (USD2.16bn) in 2014; +8.8% in local currency terms and 6.8% in US dollar terms.

Risk/Reward Rating

Sri Lanka's Pharmaceutical Risk/Reward Rating (RRR) score for Q314 stands at 38.2 out of 100, making it the seventeenth-most attractive pharmaceutical market in the Asia Pacific region.

Key Trends And Developments

  • Bangladesh and Sri Lanka have signed a Memorandum of Understanding (MOU) for the procurement of pharmaceutical and medical devices. The MOU will help Bangladesh become an important partner in Sri Lanka's socio-economic development, according to Sri Lanka's health minister, Maithripala Sirisena. The Sri Lankan government will be able to maintain a high standard of healthcare in the country, and will ensure the uninterrupted supply of high quality, reasonably priced essential medicines in Sri Lanka, Sirisena added. This is the first pharmaceutical procurement MOU signed by the Sri Lankan government with any institution or government.

  • In June 2014,  Cipla (Mauritius), a subsidiary of the Indian drugmaker Cipla, signed a definitive agreement with its existing Sri Lankan distributor to acquire a 60%...

Table of Contents

BMI Industry View
7
SWOT
9
Political
11
Economic
12
Business Environment
13
Industry Forecast
14
Pharmaceutical Market Forecast
14
Table: Pharmaceutical Sales, Historical Data And Forecasts (Sri Lanka 2010-2018)
15
Healthcare Market Forecast
16
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Sri Lanka 2010-2018)
17
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Sri Lanka 2010-2018)
17
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Sri Lanka 2010-2018)
18
Prescription Drug Market Forecast
19
Pharmaceutical Trade Forecast
20
Table: Pharmaceutical Trade Data And Forecasts (Sri Lanka 2012-2018)
21
Table: Pharmaceutical Trade Data And Forecasts local currency (Sri Lanka 2012-2018)
22
Other Healthcare Data
23
Key Risks To BMI's Forecast Scenario
25
Macroeconomic Forecasts
26
Economic Analysis
26
Services Sector To Remain Strong
27
Possible UN Resolution Unlikely To Hurt Economic Growth
28
Risks To Outlook
28
Table: Economic Activity (Sri Lanka 2009-2018)
28
Industry Risk Reward Ratings
29
Asia Risk/Reward Ratings
29
Sri Lanka Risk/Reward Ratings
35
Rewards
35
Risks
35
Market Overview
36
Industry Trends And Developments
37
Epidemiology
37
Healthcare Sector
41
Hospital Infrastructure
42
Healthcare Financing
44
Clinical Trials
45
Regulatory Development
46
Regulatory Regime
46
Regulatory Developments
48
Counterfeits
50
Pricing And Reimbursement Regimes
52
Pricing And Reimbursement Developments
53
Supply Chain
53
Competitive Landscape
56
Pharmaceutical Industry
56
Table: Local Drug Manufacturers
57
Pharmaceutical Industry Developments
58
Pharmaceutical Distribution And Retail
59
Company Profile
60
State Pharmaceuticals Corporation (SPC)
60
Hemas Holdings
64
GlaxoSmithKline
67
Demographic Forecast
70
Table: Sri Lanka's Population By Age Group, 1990-2020 ('000)
71
Table: Sri Lanka's Population By Age Group, 1990-2020 (% of total)
72
Table: Sri Lanka's Key Population Ratios, 1990-2020
73
Table: Sri Lanka's Rural And Urban Population, 1990-2020
73
Glossary
74
Methodology
76
Pharmaceutical Expenditure Forecast Model
76
Healthcare Expenditure Forecast Model
76
Notes On Methodology
77
Risk/Reward Ratings Methodology
78
Ratings Overview
79
Table: Pharmaceutical Risk/Reward Ratings Indicators
79
Indicator Weightings
80

The Sri Lanka Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Sri Lanka Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Sri Lankan pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Sri Lanka to test other views - a key input for successful budgeting and strategic business planning in the Sri Lankan pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Sri Lankan pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Sri Lanka.
  • Assess the activities, strategy and market position of your competitors, partners and clients via our Company Profiles (inc. SWOTs, KPIs and latest activity) and Competitive Landscape Tables.

Coverage

BMI Industry View & Industry SWOT

An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI's forecast analysis, and taken together with BMI's political, economic and business environment SWOTS, it gives a complete overview of market climate.

Market Summary

Snapshot of key market characteristics, including total size of pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as an analysis of the overall regulatory burden.

Industry Developments

Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

BMI Industry Forecasts

Forecasts to end-2018 for all key industry indicators (see list below) supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:

Healthcare: Total healthcare expenditure (US$bn), healthcare expenditure (% of GDP), healthcare expenditure per capita (US$), hospital beds (per `000 population), doctors (per `000 population), birth and mortality rate (per `000 population)

Pharmaceutical market: Drug expenditure (US$bn), drug expenditure (% of GDP), drug expenditure per capita (US$)

Patented drug market: Prescription drug sales (US$bn), prescription sales (% of total sales), sales broken down by 14 therapeutic areas (cardiovascular, anti-infectives etc.)

Generic drug market: Generic product sales (US$bn), generic sales (% of total sales)

OTC drug market: OTC sales (US$bn), OTC sales (% of total sales), sales broken down by product types (analgesics, skin treatments, vitamins and minerals etc.)

Medical Devices: Medical device sales (US$bn), medical device sales (% of total healthcare market)

Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt.

Competitive Landscape

The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

Company Profiles

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI's industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%

Testimonials

'An essential, multi-faceted research tool. BMI’s thorough understanding of the major market players enables an informed – and informative – review of the sector’s actual performance, together with useful insights into current industry issues, which are topped-off with detailed and invaluable forecasts of industry and macroeconomic trends.’

Senior Research Analyst, ABC International Bank plc